1. Incidence of Staphylococcus aureus with reduced susceptibility to glycopeptides in two French hospitals 
M.E. Reverdy, S. Jarraud, S. Bohin-Duhreux, E. Buret, P. Girardo, G. Lina, F. Vandenesch, J. Etienne 
Clinical Microbiology and Infection 
Volume 7, Issue 5, Pages (May 2001)
DOI: /j x x
Copyright © 2001 European Society of Clinical Infectious Diseases Terms and Conditions

2. Figure 1
Vancomycin and teicoplanin MICs for 81 S. aureus isolates, determined by the agar dilution (▪) or E test method (□).
Clinical Microbiology and Infection 2001 7, DOI: ( /j x x)
Copyright © 2001 European Society of Clinical Infectious Diseases Terms and Conditions

3. Figure 2
Population analysis of S. aureus strains PAD, GUE and MER and of control strain ATCC Bacteria grown overnight were serially diluted and plated on various concentrations of vancomycin-containing agar medium.
Clinical Microbiology and Infection 2001 7, DOI: ( /j x x)
Copyright © 2001 European Society of Clinical Infectious Diseases Terms and Conditions

4. Figure 3
Schematic representation of the pulsotypes of methicillin-resistant GISA or hGISA isolates (PAD245, PAD346, PAD438, GUE, LIM-2, and Mu50) with their respective origin from France or Japan, methicillin-resistant hGISA isolate (Mu3), methicillin-susceptible hGISA isolate (MER) and control isolates (ATCC and ATCC 29213). S. aureus NCTC 8325 was used as a size marker. Fragment sizes in the upper margin are in kb.
Clinical Microbiology and Infection 2001 7, DOI: ( /j x x)
Copyright © 2001 European Society of Clinical Infectious Diseases Terms and Conditions

5. Figure 4
Composite picture showing the morphology of vancomycin-susceptible S. aureus strain ATCC (A), and morphologic abnormalities of GISA strain PAD (B) and hGISA strains GUE (C) and MER (D). Magnification ×
Clinical Microbiology and Infection 2001 7, DOI: ( /j x x)
Copyright © 2001 European Society of Clinical Infectious Diseases Terms and Conditions